Clinical Trials Browser

Phase 1/2 × Leukemia, Lymphocytic, Chronic, B-Cell × Amplified Fragment Length Polymorphism Analysis × Clear all

NCT01269385 2020-06-23

Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

Phase 1/2 Completed

22 enrolled 9 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell